Ástralía - enska - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - solifenacin succinate, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; maize starch; hypromellose; titanium dioxide; purified talc; iron oxide yellow; macrogol 6000 - solifenacin lupin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Bandaríkin - enska - NLM (National Library of Medicine)

msn laboratories private limited - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablet is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2)] , - with gastric retention [see warnings and precautions (5.3)] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2)] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during th

Bandaríkin - enska - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablet is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2)] , - with gastric retention [see warnings and precautions (5.3)] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2)] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during th

Bandaríkin - enska - NLM (National Library of Medicine)

golden state medical supply, inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: - with urinary retention [see warnings and precautions (5.2)], - with gastric retention [see warnings and precautions (5.3)], - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema

Bandaríkin - enska - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients: • with urinary retention [see warnings and precautions (5.2) ], • with gastric retention [see warnings and precautions (5.3) ], • with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5) ], and • who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingradients in solifenacin succinate. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2) ]. risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the period o

Bandaríkin - enska - NLM (National Library of Medicine)

american health packaging - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients with: - urinary retention [see warnings and precautions ( 5.2)], - gastric retention [see warnings and precautions ( 5.3)], - uncontrolled narrow-angle glaucoma [see warnings and precautions ( 5.5)], and - in patients who have demonstrated hypersensitivity to the drug [see adverse reactions ( 6.2)]. pregnancy category c there are no adequate and well-controlled studies in pregnant women. reproduction studies have been performed in mice, rats and rabbits. after oral administration of 14 c-solifenacin succinate to pregnant mice, drug-related material was shown to cross the placental barrier. no embryotoxicity or teratogenicity was observed in mice treated with 1.2 times (30 mg/kg/day) the expected exposure at the maximum recomme

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - solifenacin succinate 5 mg - eq. solifenacin 3,8 mg - film-coated tablet - 5 mg - solifenacin succinate 5 mg - solifenacin

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - solifenacin succinate 10 mg - eq. solifenacin 7,5 mg - film-coated tablet - 10 mg - solifenacin succinate 10 mg - solifenacin

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - solifenacin succinate 5 mg - eq. solifenacin 3,8 mg - film-coated tablet - 5 mg - solifenacin succinate 5 mg - solifenacin

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - solifenacin succinate 10 mg - eq. solifenacin 7,5 mg - film-coated tablet - 10 mg - solifenacin succinate 10 mg - solifenacin